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Background: YKL-40 is a chitinase-like protein that, in cross-sectional clinical studies, has been
associated with severe asthma and COPD in smokers.
Aim: To determine the longitudinal relation of circulating YKL-40 to levels and decline of lung
function in the general population.
Methods: We used longitudinal data from up to 13 surveys from the population-based TESAOD
study which was conducted in Tucson, Arizona between 1972 and 1996. In cross-sectional an-
alyses, we also used data from 3 Spanish centers of the multicenter ECRHS study (ECRHS-Sp).
Serum YKL-40 was measured at baseline in TESAOD and in survey 2 in ECRHS-Sp using ELISAs.
Multivariate linear regression was used to test associations of serum YKL-40 to concomitant
lung function. In TESAOD, random coefficients models were used to test associations of serum
YKL-40 to subsequent decline of lung function.piratory Center, 1501 N Campbell Ave, Tucson, AZ 85724-5030, USA. Tel.: þ1 520 626 7411.
zona.edu (S. Guerra).
3 Elsevier Ltd. All rights reserved.
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1924 S. Guerra et al.Results: Data on YKL-40 and lung function were available from 1088 TESAOD and 854 ECRHS-Sp
adult participants (59% and 51% females; respectively). In adjusted multivariate meta-
analyses, being in the highest YKL-40 quartile was associated cross-sectionally with significant
deficits in FEV1 and FVC %predicted. In adjusted longitudinal analyses, TESAOD participants in
the top YKL-40 quartile had an FEV1 decline that was 5 ml/yr (pZ 0.05) faster than subjects in
the third quartile, 5 ml/yr (pZ 0.02) faster than subjects in the second quartile, and 10 ml/yr
(p < 0.001) faster than subjects in the lowest YKL-40 quartile. These longitudinal effects were
particularly strong in smokers and absent in never smokers. After adjusting for covariates, as
compared with the other three quartiles combined, the top YKL-40 quartile was associated
with a 9 ml/yr (p Z 0.001) faster FEV1 decline among smokers, while no significant effects
were found among never smokers (2 ml/yr, p Z 0.35).
Conclusions: Circulating YKL-40 is associated with levels and decline of lung function in the
general population and may be a biomarker of susceptibility to the long-term effects of ciga-
rette smoking.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The need for integrating molecular biomarkers in risk pre-
diction and clinical assessment of chronic lung diseases is
widely acknowledged [1,2]. However, at the present time
there is a lack of informative biomarkers that can be used
to identify subjects susceptible to pulmonary disease and
lung function deficits in response to specific environmental
exposures.
YKL-40 is a glycoprotein that is encoded by the CHI3L1
gene and belongs to the 18 glycosyl-hydrolase family of
chitinases and chitinase-like proteins, which have been
studied in recent years as possible biomarkers of obstruc-
tive lung diseases [3]. In the first study on YKL-40 and
asthma [4], patients with severe disease were found to
have higher YKL-40 levels in bronchial biopsies and serum
than controls. Subsequent reports [5e9] confirmed airway
and systemic YKL-40 levels to be associated with markers of
asthma severity, such as frequency of exacerbations.
Recent studies have also assessed YKL-40 in chronic
obstructive pulmonary disease (COPD). In cross-sectional
case-control studies [10e12], serum YKL-40 levels were
found to increase with pack-years of cigarette smoking and
to be higher in smokers with COPD than in smokers with no
COPD and non-smoker controls. Similar associations with
smoking and COPD status were also found when YKL-40 was
assessed directly in the airways, either in bronchoalveolar
lavage (BAL) or lung biopsies [10,11].
Although the biological functions of YKL-40 are still
incompletely understood, in vitro and in vivo studies indi-
cate a possible role of this molecule in Th2 adaptive im-
munity, lung fibrosis and remodeling, and airway
inflammation [3]. Indeed, data from several of the above
studies [4e6,9,10,12] showed inverse associations between
YKL-40 and lung function. A cross-sectional relation of
elevated YKL-40 levels from blood and/or airway samples to
lower forced expiratory volume in one second (FEV1) has
been established in patients with asthma [4,6,9] and,
although with conflicting results [11], it has also been re-
ported in patients with COPD [10,12] and in a sample from
the general population [5]. These studies were cross-
sectional and for most part based on clinical populations.To date, no longitudinal data are available on the possible
role of this biomarker in lung function decline. The goal of
our study was to determine the relation of circulating YKL-
40 to levels and decline of lung function in the general
population.Methods
Study populations and design
Study populations and study design are summarized in
Fig. E1. For this study, we used the Tucson Epidemiological
Study of Airway Obstructive Disease (TESAOD) and, in cross-
sectional analyses, also the independent cohort of the Eu-
ropean Community Respiratory Health Survey (ECRHS).
TESAOD is a population-based prospective cohort study
of non-Hispanic white households initiated in Tucson, Ari-
zona in 1972. Details of the enrollment process have been
previously reported [13]. At baseline and in 12 follow-up
surveys completed approximately every two years up to
1996, participants completed a standardized respiratory
questionnaire and e with the only exception of survey 4 e
spirometric lung function tests according to methods pre-
viously described [14]. For the present study, we used data
from 1088 participants who were 21e70 years old at
enrollment, had available serum samples with sufficient
volume from the baseline survey, and had completed lung
function tests at baseline and in at least one follow-up
survey.
ECRHS is a study involving multiple centers mainly in
Europe. Detailed methods of the study are described else-
where [15]. For the present study, we used data from
participants from the Spanish centers of Barcelona, Gal-
dakao, and Albacete (hereafter ECRHS-Sp). Briefly, in
1991e93 a random sample of individuals aged 20e44 years
was enrolled. An enrichment sample of subjects who re-
ported taking currently asthma medication or having had
asthma attacks or shortness of breath at night during the
last year were also recruited. Participants completed a
detailed questionnaire and spirometric lung function tests
at baseline and in a follow-up survey taken about 9 years
Serum YKL-40 and lung function 1925later. A total of 854 ECRHS-Sp participants (637 from the
random and 217 from the enriched sample) who completed
questionnaire and lung function tests and had available
serum samples of sufficient volume from survey 2 were
included in this study.
YKL-40 measurements
Serum YKL-40 was measured using the same procedures and
commercially available enzyme-linked immunosorbent as-
says kit (Quantikine Human CHI3L1 immunoassay by R&D,
Inc, Minneapolis, MN, USA, and Abingdon, UK) in both
populations. Further details are provided in the Online
supplement. Serum samples came from the baseline sur-
vey in TESAOD and the follow-up survey in ECRHS-Sp
(no serum samples were available from the baseline sur-
vey in ECRHS-Sp).
Lung function
Consistent with previous studies, in TESAOD percent pre-
dicted values for lung function indices were computed using
reference equations generated from the same population
by Knudson and colleagues [16]. In ECRHS-Sp, reference
equations by Hankinson et al. [17] were used. In both co-
horts, spirometric patterns were defined as normal (FEV1/
FVC  70% and forced vital capacity [FVC]  80% pre-
dicted), restrictive (FEV1/FVC  70% and FVC < 80% pre-
dicted), or obstructive (FEV1/FVC < 70% independent of
FVC values).
Other exposure and phenotype variables
With the exception of lung function indices in TESAOD,
which were modeled longitudinally, all other exposure and
phenotype variables were assessed at the same survey in
which YKL-40 measurements were completed, i.e., the
baseline survey in TESAOD and the follow-up survey in
ECRHS-Sp. A description of these variables is provided in
the Online supplement.
In both cohorts, physician-confirmed asthma was defined
as a positive report that a physician told the participant
that he or she had asthma. Asthma was defined as active if
the participant reported to have had any asthma attacks in
the past year or to be currently taking any asthma
medications.
Statistical analyses
Because distribution of YKL-40 levels was skewed to the
right, values were log-transformed when used on a
continuous scale. YKL-40 values were categorized into
quartiles and analyses were completed by contrasting the
top quartile against the other three quartiles separately to
study the effects of high YKL-40 on lung health. Results
from analyses contrasting the top quartile (high YKL-40)
against the other three quartiles combined (low-medium
YKL-40) are shown in the Online supplement.
In cross-sectional analyses, for each lung function
index (FEV1, FVC, and FEV1/FVC ratio) linear regression
models were fitted in TESAOD and ECRHS-Sp separately. Ifcoefficients associated with having high YKL-40 were found
not to be different between TESAOD and ECRHS-Sp by
heterogeneity test, combined estimates were obtained by
meta-analysis.
In TESAOD, YKL-40 was measured at baseline and could
be studied prospectively in relation to decline of lung
function. In order to study the effects of elevated YKL-40 on
subsequent decline of lung function while adjusting for the
intra-subject serial correlation of repeated observations,
we used random coefficients models [18] that included
covariates and an interaction term between YKL-40 quar-
tiles and years of follow-up to predict FEV1, FVC, and the
ratio FEV1/FVC, respectively. This interaction term tested
whether the decline of the specific lung function index
differed between subjects in the top YKL-40 quartile and
subjects in the other YKL-40 quartiles. An unstructured
covariance structure was chosen for all models. To rule out
that YKL-40 effects on subsequent decline of lung function
were due to effects on initial levels of lung function, we also
ran mixed models for each lung function index by excluding
observations from survey 1 from the dependent variable and
including % predicted values of the specific lung function
index at the baseline survey among covariates.
A group variable based on the combination of YKL-40
(top quartile versus the other three quartiles combined)
and smoking (ever versus never) was also generated and
tested in random coefficients models in order to depict
graphically expected levels and decline of FEV1 over the
TESAOD study follow-up across the four groups.
Results
Demographic, behavioral, and clinical characteristics of
TESAOD participants are summarized in Table 1. Overall,
the study participants had a mean age of 46 years and
included 59% females, 60% ever smokers, and 11% asth-
matics. The mean and median levels of serum YKL-40 were
46.5 and 34.0 ng/ml, respectively.
Associations of serum YKL-40 with demographic factors
and smoking behavior are summarized in Table E2. YKL-40
levels correlated strongly and significantly with age
(Spearman correlation coefficient 0.41, p < 0.001) and with
pack-years (0.26, p < 0.001).
Cross-sectional associations of YKL-40 with asthma
and lung function in TESAOD
No cross-sectional significant associations were found be-
tween YKL-40 levels and physician confirmed asthma (Table
E3). Among asthmatics, YKL-40 levels were not affected by
disease activity, age at onset, or atopic status. However,
serum YKL-40 levels were higher in asthmatics with lung
function deficits (i.e., FEV1% predicted < 80%) than in
subjects with no asthma or asthmatics with no lung function
deficits.
YKL-40 levels were higher in participants with spiro-
metric restrictive and moderate/severe obstructive pat-
terns than in subjects with normal spirometry (Fig. E2a).
Consistent with this observation, serum YKL-40 levels
correlated significantly and inversely with concomitant
FEV1% predicted (Spearman correlation coefficient: 0.12;
Table 1 Baseline characteristics of TESAOD participants
at the time of blood collection.
N 1088
Females: N (%) 639/1088 (58.7%)
Age: mean; range in years 46 (21e70)
Body Mass Index: N (%)
Under-weight (<18.5 kg/m2) 21 (2.0%)
Normal-weight
(18.5, <25 kg/m2)
612 (58.2%)
Over-weight (25, <30 kg/m2) 344 (32.7%)
Obese (30 kg/m2) 75 (7.1%)
Smoking status: N (%)
Never 431 (39.7%)
Former 268 (24.7%)
Current 388 (35.7%)
Smoke intensity in pack-years: N (%)
0 pack-years 431 (39.7%)
>0; 10 pack-years 210 (19.3%)
>10; 20 pack-years 141 (13.0%)
>20; 40 pack-years 170 (15.7%)
>40 pack-years 134 (12.3%)
Physician-confirmed asthma: N (%)
Never 965 (88.8%)
Inactive 52 (4.8%)
Active 70 (6.4%)
Atopya: N (%) 412/1075 (38.3%)
Spirometric patterns: N (%)
Normal 846 (77.8%)
Restrictive 114 (10.5%)
Obstructive 128 (11.8%)
FEV1% predicted: mean; SD 94.8% (18)
FVC% predicted: mean; SD 97.5% (17)
FEV1/FVC ratio %: mean; SD 80.2% (10)
YKL40: mean; median;
IQR in ng/ml
46.5; 34.0; 23.5e54.3
a Defined as having a skin prick test wheal 2 mm larger than
control for one of 5 tested allergens.
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FVC levels (0.12; p < 0.001).Replication of cross-sectional associations in
ECRHS-Sp
Characteristics of ECRHS-Sp participants are given in Table
E1. As compared with TESAOD, the ECRHS-Sp study popu-
lation was on average 5-years younger and had a narrower
age range and a higher BMI. However, the two populations
had relatively comparable rates of ever smoking, heavy
smoking, and physician-confirmed asthma. Like in TESAOD,
also in ECRHS-Sp serum YKL-40 levels correlated with age
and pack-years (Table E2). In ECRHS-Sp, higher YKL-40
levels were also found in males and current smokers.
The findings of increased YKL-40 levels in asthmatics with
lung function deficits and in subjects with abnormal spiro-
metric patterns that were observed in TESAOD were repli-
cated in ECRHS-Sp (Table E3 and Fig. E2b). Similar to
TESAOD, in ECRHS-Sp serum YKL-40 levels correlated
inversely with FEV1% predicted (Spearman correlationcoefficient: 0.21; p < 0.001), FVC % predicted (0.19;
p < 0.001), and FEV1/FVC levels (0.17; p < 0.001). In an-
alyses by YKL-40 quartiles, in both cohorts subjects in the top
YKL-40 quartile had lower FEV1% predicted, FVC % predicted,
and FEV1/FVC levels as compared with subjects in the other
three quartiles (Table 2 and Table E4). Although adjustment
for potential confounders reduced the strength of these as-
sociations, in fully adjusted meta-analyses subjects in the
highest YKL-40 quartile were still found to have significant
deficits in both FEV1 and FVC % predicted.YKL-40 and decline of lung function in TESAOD
The TESAOD participants included in this study completed
on average 6.8 lung function tests (SD: 3; range: 2e12) over
a mean follow-up of 13.5 years (SD: 7, range: 1e23 years). A
total of 7325 lung function observations were used in mixed
models to determine the effects of YKL-40 on decline of
FEV1, FVC, and FEV1/FVC ratio.
In mixed models adjusted for sex, age, height, BMI cat-
egories, smoking status, pack-years, and asthma, increasing
rates of lung function decline were evident across YKL-40
quartiles (Table 3), with participants in the top YKL-40
quartile at baseline having an FEV1 decline that was 5 ml/
yr (p Z 0.046) faster than subjects in the third quartile,
5 ml/yr (p Z 0.02) faster than subjects in the second
quartile, and 10 ml/yr (p < 0.001) faster than subjects in
the lowest YKL-40 quartile. As compared with the third,
second, and first quartile, respectively, the corresponding
estimates for the accelerated decline associated with the
top YKL-40 quartile were 3 ml/yr (p Z 0.23), 5 ml/yr
(pZ 0.04), and 11 ml/yr (p < 0.001) for FVC; and 0.11%/yr
(pZ 0.009), 0.08%/yr (pZ 0.07), and 0.10%/yr (pZ 0.03)
for the FEV1/FVC ratio (Table 3). When the top YKL-40
quartile was contrasted against the other three quartiles
combined (Table E5), after adjusting for all covariates the
top YKL-40 quartile was found to be associated with a 7 ml/
yr (p < 0.001) faster FEV1 decline, a 7 ml/yr (p Z 0.003)
faster FVC decline, and a 0.10%/yr (pZ 0.008) faster FEV1/
FVC decline during the study follow-up. Significant YKL-40
effects on decline of lung function were confirmed after
further adjustment for levels of lung function at the base-
line survey (data not shown). Although the cut-off of the
top YKL-40 quartile was chosen a priori for statistical an-
alyses, the effects of alternative YKL-40 cut-offs on FEV1
decline were tested in exploratory analyses and a trend
from the top tertile to the top decile was found (Fig. E3),
despite differences in effects and sample size in some of
the groups were quite small.
When analyses were stratified by smoking, the effects on
subsequent decline of lung function across the four YKL-40
quartiles were found to be stronger among smokers than
never smokers (Table 3). In smokers, after adjusting for
covariates, being in the highest YKL-40 quartile at baseline
was associated with a 13 ml/yr (p < 0.001) faster FEV1
decline, a 14 ml/yr (p < 0.001) faster FVC decline, and a
0.11%/yr (p Z 0.07) faster FEV1/FVC decline as compared
with subjects in the lowest quartile (Table 3), and with a
9 ml/yr (p Z 0.001) faster FEV1 decline, a 9 ml/yr
(p Z 0.003) faster FVC decline, and a 0.11%/yr (p Z 0.03)
faster FEV1/FVC decline as compared with subjects in the
Table 2 Cross-sectional associations between YKL-40 quartiles and lung function in TESAOD and ECRHS-Sp populations.
b coefficients (95% CIs) from regression models
Unadjusted Fully adjusted
TESAOD
(N Z 1088)
ECRHS-Sp
(N Z 854)
Meta-analysis
(N Z 1942)
TESAOD*
(N Z 1085)
ECRHS-Sp**
(N Z 844)
Meta-analysis
(N Z 1929)
FEV1% predicted
1st YKL-40
quartile
6.8% (3.8, 9.8) 8.6% (5.8, 11.3) 7.8% (5.8, 9.8) 2.6% (0.5, 5.7) 3.5% (0.8, 6.3) 3.1% (1.0, 5.2)
2nd YKL-40
quartile
5.6% (2.6, 8.7) 7.2% (4.4, 9.9) 6.5% (4.4, 8.5) 2.0% (1.0, 5.1) 4.0% (1.3, 6.6) 3.1% (1.1, 5.2)
3rd YKL-40
quartile
5.0% (2.0, 8.0) 4.5% (1.7, 7.2) 4.7% (2.7, 6.7) 1.6% (1.4, 4.5) 2.5% (0.1, 5.1) 2.1% (0.1, 4.0)
4th YKL-40
quartile
Reference Reference Reference Reference Reference Reference
FVC% predicted
1st YKL-40
quartile
6.1% (3.4, 8.9) 7.1% (4.7, 9.5) 6.7% (4.9, 8.5) 3.4% (0.4, 6.4) 3.9% (1.4, 6.4) 3.7% (1.8, 5.6)
2nd YKL-40
quartile
4.9% (2.1, 7.7) 5.3% (2.9, 7.7) 5.1% (3.3, 6.9) 2.5% (0.4, 5.4) 3.0% (0.6, 5.4) 2.8% (1.0, 4.6)
3rd YKL-40
quartile
4.5% (1.8, 7.3) 3.0% (0.6, 5.3) 3.6% (1.9, 5.4) 2.4% (0.4, 5.2) 1.6% (0.7, 4.0) 1.9% (0.1, 3.7)
4th YKL-40
quartile
Reference Reference Reference Reference Reference Reference
FEV1/FVC in %
1st YKL-40
quartile
3.6% (2.0, 5.2) 3.1% (1.8, 4.5) 3.3% (2.3, 4.3) 0.2% (1.8, 1.4) 0% (1.3, 1.3) 0.1% (1.1, 0.9)
2nd YKL-40
quartile
2.8% (1.2, 4.4) 3.2% (1.8, 4.5) 3.0% (2.0, 4.1) 0.1% (1.7, 1.4) 1.0% (0.3, 2.3) 0.6% (0.3, 1.5)
3rd YKL-40
quartile
2.3% (0.7, 3.9) 2.4% (1.1, 3.8) 2.4% (1.3, 3.4) 0.2% (1.7, 1.3) 0.9% (0.3, 2.1) 0.5% (0.4, 1.4)
4th YKL-40
quartile
Reference Reference Reference Reference Reference Reference
b coefficients correspond to unadjusted and adjusted differences in lung function parameters for subjects in the first, second, and third
YKL-40 quartile as compared with subjects in the highest quartile, respectively. Results are from simple and multivariate regression
models predicting FEV1% predicted, FVC% predicted, and the FEV1/FVC ratio, respectively. Lung function indices are from the same
survey when blood for YKL-40 measurements was collected (i.e., survey 1 in TESAOD and survey 2 in ECRHS-Sp).
*Adjusted for sex, age, smoking status, pack-years, BMI categories, and asthma for TESAOD.
**Adjusted for sex, age, smoking status, pack-years, BMI categories, asthma, sample type (random versus enriched), and center for
ECRHS-Sp.
Serum YKL-40 and lung function 1927other three quartiles combined (Table E5). In contrast,
among never smokers serum YKL-40 was not significantly
associated with decline in any of the lung function indices
(Table 3 and Table E5). No interactive effects between YKL-
40 and age at enrollment were found on subsequent decline
of lung function (data not shown).
Consistent with the findings above, fully adjusted mixed
models showed that smokers with high YKL-40 had a decline
of lung function during the study follow-up that was
significantly faster than that of any other group (i.e.,
smokers with low-medium YKL-40, non-smokers with high
YKL-40, and non-smokers with low-medium YKL-40) (Fig. 1).Discussion
This is the first prospective study to address serum YKL-40
in relation to levels and decline of lung function. Our
findings show that, cross-sectionally, serum YKL-40 isconsistently associated with both FEV1 and FVC deficits in
the general population and that these associations are
partially independent of other known predictors of lung
function, including asthma. Most importantly, they indicate
that longitudinally subjects with elevated YKL-40 have a
decline of lung function that is faster than that of subjects
with low or medium YKL-40 and that these effects are
synergistic with those of cigarette smoking. Both in cross-
sectional and prospective analyses, the magnitude of YKL-
40 associations was stronger with FEV1 and FVC values
than with the FEV1/FVC ratio.
Subjects who both smoked and had elevated YKL-40 at
baseline experienced the steepest decline of FEV1 and FVC
during the study follow-up, with an estimated additional
FEV1 decline of 9 ml/yr compared with smokers with low-
medium YKL-40 and 13 ml/yr compared with smokers in
the lowest YKL-40 quartile after adjusting for covariates
that included pack-years as a quantitative assessment of
smoking exposure. Although the impact of smoking on FEV1
Table 3 Longitudinal associations between YKL-40 at baseline and lung function decline during follow up in the TESAOD
cohort. Coefficients (95% CIs) correspond to adjusted differences between subjects in the first, second, and third YKL-40
quartile as compared with subjects in the highest quartile (ref category) in rate of decline of FEV1, FVC, and FEV1/FVC ratio
during the study follow-up in the total population, among never smokers, and ever smokers.
Differences in rate of lung function decline between each of the other three quartiles and the
highest YKL-40 quartile (positive coefficient indicates slower decline as compared with the
highest YKL-40 quartile)
Total population
N subjects Z 1085
N observations Z 7325
Never smokers
N subjects Z 431
N observations Z 3026
Smokers
N subjects Z 654
N observations Z 4299
Fully adjusteda
Coefficients (95% CI)
Fully adjustedb
Coefficients (95% CI)
Fully adjusteda
Coefficients (95% CI)
Differences in FEV1 decline in ml/yr
1st YKL-40 quartile 10 (5, 14) ml/yr
p< 0.001
5 (0, 10) ml/yr
p Z 0.06
13 (6, 19) ml/yr
p< 0.001
2nd YKL-40 quartile 5 (1, 10) ml/yr
p Z 0.02
1 (6, 5) ml/yr
p Z 0.78
9 (3, 16) ml/yr
p Z 0.004
3rd YKL-40 quartile 5 (0, 9) ml/yr
p Z 0.046
2 (4, 8) ml/yr
p Z 0.46
6 (0, 13) ml/yr
p Z 0.049
4th YKL-40 quartile Reference Reference Reference
Differences in FVC decline in ml/yr
1st YKL-40 quartile 11 (6, 16) ml/yr
p< 0.001
7 (0, 14) ml/yr
p Z 0.04
14 (6, 21) ml/yr
p< 0.001
2nd YKL-40 quartile 5 (0, 11) ml/yr
p Z 0.04
0 (7, 7) ml/yr
p Z 0.97
10 (2, 17) ml/yr
p Z 0.01
3rd YKL-40 quartile 3 (2, 9) ml/yr
p Z 0.23
0 (7, 8) ml/yr
p Z 0.92
5 (2, 13) ml/yr
p Z 0.15
4th YKL-40 quartile Reference Reference Reference
Differences in FEV1/FVC decline in %/yr
1st YKL-40 quartile 0.10 (0.01, 0.18) %/yr
p Z 0.03
0.05 (0.06, 0.15) %/yr
p Z 0.41
0.11 (0.01, 0.24) %/yr
p Z 0.07
2nd YKL-40 quartile 0.08 (0.01, 0.16) %/yr
p Z 0.07
0.02 (0.09, 0.13) %/yr
p Z 0.74
0.11 (0.01, 0.23) %/yr
p Z 0.07
3rd YKL-40 quartile 0.11 (0.03, 0.20) %/yr
p Z 0.009
0.10 (0.01, 0.21) %/yr
p Z 0.08
0.12 (0, 0.24) %/yr
p Z 0.051
4th YKL-40 quartile Reference Reference Reference
a From mixed models adjusted for sex, age at enrollment, height, smoking status, pack-years, BMI categories, and asthma.
b From mixed models adjusted for sex, age at enrollment, height, BMI categories, and asthma.
1928 S. Guerra et al.decline is highly dependent on the number of cigarettes
smoked per day, a systematic review estimated that
continuing smoking was associated on average with an
11 ml/yr increase in FEV1 decline [19]. These observations
suggest that the combined lung function deficits associated
with smoking and high YKL-40 may be clinically important
and that e in conjunction with other known determinants
of risk prediction e elevated serum YKL-40 may prove
helpful in identifying smokers who are susceptible to the
effects of smoking on lung health. Although secondary an-
alyses in our study suggested that YKL-40 cut-offs higher
than the top quartile may be more powerful in predicting
subsequent decline of lung function, specifically designed
studies will be required to conclusively establish optimal
YKL-40 cut-off levels for risk prediction.
The YKL-40 effects on decline of lung function were at
least partly independent of asthma because they held true
after adjustment for asthma. Indeed, in our two
population-based cohorts e in which a substantial part of
asthma cases are expected to be mild e we did not find anassociation between increased serum YKL-40 and asthma
per se, whereas we did find YKL-40 to be elevated in those
asthma cases who presented with concomitant lung func-
tion deficits. Previous studies [4,6,7,9] have associated
YKL-40 levels with several markers of asthma severity,
including lung function deficits. Similarly in the original
study by Chupp and colleagues [4], after adjusting for
covariates, subjects with moderate and severe asthma, but
not those with mild asthma, had higher serum YKL-40 than
controls. All these observations are consistent with the
possibility that YKL-40 is a biomarker of severity of asthma.
Whether YKL-40 is also associated with lung function defi-
cits that may precede adult onset asthma [20] and in turn it
may be useful in risk prediction of asthma incidence re-
mains to be determined.
Although our findings are based on observational data,
several studies suggest that smoking exposure directly in-
creases expression of YKL-40 and implicate YKL-40 as a po-
tential mediator of the lung inflammatory response to
cigarette smoke. First, murine models have demonstrated
Figure 1 FEV1 levels at baseline and decline during the study
follow-up as predicted from fully adjusted random coefficients
models for TESAOD groups of subjects with low-medium YKL-40
(i.e., three bottom quartiles combined) who never smoked
(green line; number of subjects Z 333; number of
observations Z 2385), subjects with low-medium YKL-40 who
smoked (black line; number of subjects Z 481; number of
observations Z 3238), subjects with high YKL-40 (i.e., top
quartile) who never smoked (yellow line; number of
subjects Z 98; number of observations Z 641), and subjects
with high YKL-40 who smoked (red line; number of
subjects Z 173; number of observations Z 1061). Depicted
values represent predicted values for a 175-cms tall male who
was 45 years old at baseline and had no asthma and normal
weight.
Footnote for Figure 1:
Linear contrasts for pair-wise comparisons of rates of
FEV1 decline that were significant after Bonferroni
correction:
- “Low-medium YKL-40/Smk” steeper than “Low-me-
dium YKL-40/No smk”; p Z 0.008
- “High YKL-40/Smk” steeper than “Low-medium YKL-
40/No smk”; p < 0.001
- “High YKL-40/Smk” steeper than “Low-medium YKL-
40/Smk”; p < 0.001
- “High YKL-40/Smk” steeper than “High YKL-40/No
smk”; p Z 0.001.
Serum YKL-40 and lung function 1929over-expression of breast regression protein 39 (BRP-39, the
murine equivalent of YKL-40) in alveolar macrophages and
airway epithelial cells following cigarette smoke exposure
[11,21]. Second, stimulation of alveolar macrophages with
TNF-a promoted release of YKL-40 and this effect was
enhanced in smokers e particularly those with COPD.
Increased production of inflammatory and fibrogenic medi-
ators by alveolar macrophages stimulated with YKL-40 was
also preferentially observed in cells obtained from smokers
with COPD [10]. Finally BRP-39/ mice showed a blunted
inflammatory response following chronic exposure to ciga-
rette smoking [11], although they also had an enhanced
alveolar destruction whichmight suggest a protective role ofeither BRP-39 or other aspects of the blunted inflammatory
response in regard to alveolar destruction.
Yet, whether YKL-40 is causally or indirectly implicated
in smoking-related damage to the lungs remains unknown.
It also remains to be determined if the involved mecha-
nisms are independent of other alternative pathways e
such as allergen induced Th2 inflammation [22] and bron-
chial smooth muscle remodeling [23,24] e that have been
proposed for effects on asthma severity. YKL-40 has been
linked to severity and outcomes in a number of other dis-
eases characterized by inflammation and tissue remodeling
(reviewed by Lee et al. [3]) and with all-cause mortality in
the general population [25e27]. While this observation ar-
gues against YKL-40 being a lung specific biomarker, it
suggests that this protein might be over-expressed in
smokers with COPD who also have other inflammation-
related comorbidities frequently linked to this disease
[28,29]. This hypothesis was not addressed in our study.
As is the case for most large epidemiological biomarker
studies, only one measurement at a single point in time was
available for YKL-40 from each of our cohorts. Although
previous studies have shown the within-subject coefficient
of variation of serum YKL-40 levels over 3e4 years to be
below 40% [4,30], the informative value of YKL-40 temporal
trends in risk prediction warrants future studies.
In conclusion, we found that serum YKL-40 is a
biomarker linked to lung function deficit and decline in the
general population, particularly in smokers. Being in the
top YKL-40 quartile increased the rate of FEV1 decline by
13 ml per year among smokers, as compared with smokers
in the lowest YKL-40 quartile. These findings implicate YKL-
40 as a potential biomarker of susceptibility to the long-
term effects of cigarette smoking on lung function decline
and warrant further evaluation in the preventive and clin-
ical setting.
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